ArticleEuropean journal of nuclear medicine and molecular imaging2026
Molecular imaging of lymphatic organs provides prognostic value after acute myocardial infarction.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05519735 (Multimodal Characterization of Lymphatic Organs and Myocardium in Patients After Acute Myocardial Infarction), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multimodal Characterization of Lymphatic Organs and Myocardium in Patients After Acute Myocardial Infarction
Who cites it
2 citing papers in PubMed.
- Lymphatic Endothelial Cells in Health and Disease.MedComm · 2026Review
- A novel non-invasive approach monitoring skeletal stem cell function throughJournal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcute myocardial infarction (AMI) triggers local inflammation in the injured myocardium, followed by a systemic inflammatory response of lymphatic organs. This prospective trial (NCT05519735) focused on molecular imaging of lymphatic organs (spleen, bone marrow, and heart-draining lymph nodes) and aimed to determine whether uptake in such remote organs identifies individuals predisposed to functional recovery during follow-up after AMI.
methods41 timely re-perfused ST-elevation AMI patients received baseline C-X-C motif chemokine receptor 4 directed
resultsLVEF at baseline was 50.4 ± 8.7% (range 34-65%). At FU 1, LVEF improved significantly (54.2 ± 7.1%, P = 0.0004 vs. baseline) and the endpoint was recorded in 21/38 patients. Univariate analysis identified baseline LVEF (Odds Ratio (OR), 0.80, P = 0.002) and uptake derived from heart-draining lymph nodes (OR, 0.21, P = 0.03) as predictor of functional recovery, while only LVEF reached significance at multivariate analysis (OR, 0.72, P = 0.007). At FU 2, LVEF also improved to 54.3 ± 7.3% relative to baseline (P = 0.006) and the endpoint was met in 21/36 patients. Baseline LVEF (OR 0.84, P = 0.005) and splenic PET signal (OR, 2.46, P = 0.04) provided prognostic value at univariate analysis. Both parameters remained significant at multivariate outcome analysis (LVEF: OR, 0.73, P = 0.01; spleen: OR, 4.17, P = 0.04), indicating that baseline LVEF and splenic uptake are prognostic for improved long-term functional outcome. Established risk factors of cardiac damage (infarct size) or inflammation (C-reactive protein, white blood cell counts) failed to reach significance for functional recovery at both follow-up time-points.
conclusionsInflammatory imaging in lymphatic organs may provide a complementary in-vivo biomarker for functional recovery and seems to be more strongly associated with outcome relative to standard markers of cardiac damage or inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.